Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria

Table 1 Baseline characteristics

	FSGS n = 49	No FSGS n = 51	p-value
Median age, years (IQR^a)	51 (44.75 to 61.25)	55 (44.25 to 61.00)	0.7667
Gender	Females 28/49 (57%)	Females 36/51 (70%)	0.1614
Gender	Males 21/49 (43%)	Males 15/51 (30%)
Race	White 30/49 (61%)	White 36/51 (70%)
	Black 14/49 (29%)	Black 10/51 (20%)	0.5563
	Other 5/49 (10%)	Other 5/51 (10%)
Median Body Mass Index (IQR^a)	25 (21–32)	27 (24–31.5)	0.4593
Pre transplant hypertension	44/49 (89%)	37/51 (72%)	0.0279
Pre transplant diabetes	13/49 (26.5%)	12/51 (23.5%)	0.7289
Hepatitis B infection	0/49 (0%)	0/51 (0%)	NA
Hepatitis C infection	4/49 (8%)	2/51 (4%)	0.3719
HIV infection	0/49 (0%)	0/51 (0%)	NA
Use of ACEI^b or ARB^c prior to transplant	21/49 (43%)	13/51 (25.5%)	0.0668
Primary renal disease is primary FSGS	10/49 (20%)	3/51 (6%)	0.03
Primary renal disease is glomerular disease	10/49 (20%)	13/51 (25.5%)	0.5460

There were no statistically significant differences between FSGS group and the comparison group in the median age, gender, race, pre-transplant diabetes or use of ACEI or ARB prior to transplant. Pre transplant hypertension was more in the FSGS group than the comparison group, the difference was statistically significant. Primary FSGS as a cause of primary renal disease was higher in patients with FSGS to comparison group, the difference was statistically significant
^aInter Quartile Range
^bAngiotensin converting enzyme inhibitors
^cAngiotensin receptor blockers
Data are presented as proportions followed by percentage (%) unless otherwise mentioned

ISSN: 1471-2369